Functional SNP allele discovery (fSNPd): an approach to find highly penetrant, environmental-triggered genotypes underlying complex human phenotypes. by Stouffer, Kaitlin et al.
METHODOLOGY ARTICLE Open Access
Functional SNP allele discovery (fSNPd): an
approach to find highly penetrant,
environmental-triggered genotypes
underlying complex human phenotypes
Kaitlin Stouffer1†, Michael Nahorski1†, Pablo Moreno1†, Nivedita Sarveswaran1, David Menon2, Michael Lee2
and C. Geoffrey Woods1*
Abstract
Background: Significant human diseases/phenotypes exist which require both an environmental trigger event and
a genetic predisposition before the disease/phenotype emerges, e.g. Carbamazepine with the rare SNP allele of
rs3909184 causing Stevens Johnson syndrome, and aminoglycosides with rs267606617 causing sensory neural
deafness. The underlying genotypes are fully penetrant only when the correct environmental trigger(s) occur,
otherwise they are silent and harmless. Such diseases/phenotypes will not appear to have a Mendelian inheritance
pattern, unless the environmental trigger is very common (>50% per lifetime). The known causative genotypes are
likely to be protein-altering SNPs with dominant/semi-dominant effect. We questioned whether other diseases and
phenotypes could have a similar aetiology.
Methods: We wrote the fSNPd program to analyse multiple exomes from a test cohort simultaneously with the
purpose of identifying SNP alleles at a significantly different frequency to that of the general population. fSNPd was
tested on trial cohorts, iteratively improved, and modelled for performance against an idealised association study
under mutliple parameters. We also assessed the seqeuncing depath of all human exons to determine which were
sufficiently well sequenced in an exome to be sued by fSNPd - by assessing forty exomes base by base.
Results: We describe a simple methodology for the detection of SNPs capable of causing a phenotype triggered
by an environmental event. This uses cohorts of relatively small size (30–100 individuals) with the phenotype being
investigated, their exomes, and thence seeks SNP allele frequencies significantly different from expected to identify
potentially clinically important, protein altering SNP alleles. The strengths and weaknesses of this approach for
discovering significant genetic causes of human disease are comparable to Mendelian disease mutation detection
and Association Studies.
Conclusions: The fSNPd methodology is another approach, and has potentially significant advantage over
Association studies in needing far fewer individuals, to detect genes involved in the pathogenesis of a diseases/
phenotypes. Furthermore, the SNP alleles identified alter amino acids, potentially making it easier to devise
functional assays of protein function to determine pathogenicity.
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Background
Molecular genetic approaches have proved extremely
powerful to discover and dissect the genetic components
underlying many human diseases. Clear examples are: the
discovery of highly penetrant, but often very rare, patho-
genic mutations causing Mendelian diseases [1, 2]; Associ-
ation Studies using single nucleotide polymorphisms
(SNPs) with common rare allele frequencies able to
discover haplotypes causing small phenotypic effects, which
have revealed many disease processes [3–5] and in cancer
where somatic mutation detection en masse are delineating
hitherto unrecognized tumor types and leading to personal-
ized therapies [6, 7]. We describe here a further genetic
approach, functional single nucleotide polymorphism dis-
covery (fSNPd) (summarized in Fig. 1). This was designed
to detect genetic components of clinically important disor-
ders that require an environmental trigger to occur, e.g. se-
vere drug reactions, pain syndromes occurring after an
injury, and susceptibility to infection.
fSNPd relies upon SNPs, which are widespread and
frequent variations found in the genomic sequence of
individuals of a species. fSNPd does examine autosomal
and sex-chromosome SNPs. The term SNP has, by com-
mon usage, come to also include small insertions and
deletions (INDELS) in genomic DNA. SNPs have a wide-
spread distribution throughout the human genome [8].
For each SNP, the first allele is almost always the com-
moner allele, but the rarer second allele can potentially
alter the canonical protein sequence or/and protein
expression. The majority of SNP second/rare alleles are
considered harmless, or at least are not known to exert a
phenotypic effect. However, it is known that some of
these usually “silent” SNP second alleles do cause a
phenotype when combined with a specific environment
trigger, e.g. SNPs rs3909184 and rs2844682 (the geno-
type HLA-B*1502) which are phenotypically silent until
after Carbamazepine absorption when Stevens Johnson
syndrome (Toxic epidermal necrolysis) occurs, HIV
progression and G allele of rs1799987, and mitochon-
drial genome SNPs rs267606617 (m.1555A > G) and
rs267606618 (m.1095 T > C) causing sensory-neural
deafness after amino-glycoside administration [9–11].
We hypothesised that other SNPs could also cause en-
vironmental triggered diseases and phenotypes. We have
developed a simple methodology for their discovery
using small cohorts and exomes which we report here.
Results
The “exome” we used contained 19,214 genes (which
were fully or partially sequenced), and approximately
121,000 SNPs where rare alleles were called (which
varied between individual’s exomes), and of which 20%
were protein changing.
We compared these allele frequencies against “control”
allele frequencies obtained from population database
catalogues. Firstly, we used the data in the European
subset of the 1000G for SNP allele frequencies. And
secondly, and separately, the SNP allele frequency data
from the EVS [12, 13]. Where there was data in both
catalogues, most SNP allele frequencies were similar
(<5% difference in allele frequency), but for a minority
(17%) there was a potentially significant difference (>5%
difference in allele frequency). There were a number of
reasons we could identify for this discrepancy, including
the fact that some SNPs had more than two alleles in
EVS and our approach only enabled us to record the
lowest frequency SNP allele - so EVS data for these
SNPs rare alleles was incorrect. Other discordances
arose from mis-allocation of “reads” to an incorrect gene
(e.g. potassium channel genes), or from real differences
in the dataset results due to factors such as ethnic differ-
ences (e.g. MC1R allele frequencies). Thus, the utility of
producing two separate sets of results, one using the
European subset of the 1000 Genomes project for nor-
mal/control population SNP allele frequencies and the
other using Exome Variant Server (EVS) for these
frequencies, was to increase the chances of finding real
significant results but at the cost of an increased number
of false negative and false positive results.
The number of SNPs that could be accurately
sequenced in our exomes was determined, and the
results are detailed in Additional file 1: Table S1 which
gives the results per gene, and per exon of each gene.
For satisfactory coverage we used a cutoff of 20 fold
coverage, as less is regarded as insufficient to reliably
detect heterozygosity. There were data for 19,214 genes.
82% (16,023) genes had an average coverage >19 reads,
see Additional file 1: Figure. Our data analysis shows
that SNP allele frequency determination is incomplete,
but mostly predictably so between tested exomes.
To assess the performance of fSNPd for allele fre-
quency determination we analysed 100 SNPs, chosen
from two study cohorts, where allele frequencies were
found to be statistically altered and checked the results
by use of the Integrated Genome Viewer (IGV [14]); all
frequencies were accurate to 1%. We also checked seven
of the 100 SNPs by Sanger sequencing of all of the re-
spective cohorts individuals - and found allele frequency
results accurate in six, and for one SNP to within 1%.
The cause for the difference was that one of the samples
analysed for the SNP had a read depth < 20, so was not
used by fSNPd in calculating the allele frequency,
whereas it was able to be successfully Sanger sequenced
and the alleles scored.
We performed fSNPd simulations, assuming that a
rare SNP allele was fully penetrant when present (unless
otherwise stated), see Additional file 1: Table S2. For a
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Fig. 1 (See legend on next page.)
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cohort of 100, and a SNP rare allele frequency in the
normal population of 0.01 – fSNPd detected the SNP
rare disease causing allele when there were one to eight
SNPs all capable of causing the investigated phenotype;
an Association Study approach detected none with Chi
squared p value of <10−8. If we made the rare allele
frequency in the general population 0.005 then fSNPd
detected the rare SNP alleles if there were one to ten
causative SNPs. If there were only 30 subjects in the
cohort, or if we simulated half the cases of a cohort of
100 were non-genetic, or if the SNP rare allele was only
penetrant in 50% of cases, then fSNPd could detect the
SNP alleles if there were one to four causative SNPs.
And, if our cohort had 3000 individuals Association
Studies would detected the SNP alleles when there was
one to five causative SNPs, and fSNPd one to ten
causative SNPs.
Finally we illustrate the potential use of fSNPd by re-
examining two of the known examples of human
diseases/phenotypes which require both an environmen-
tal trigger event and a genetic predisposition before the
disease/phenotype emerges. Firstly, 44 patients were
reported who had Stevens–Johnson syndrome after tak-
ing carbamazepine, all had the G allele of the HLA-B
SNP rs3909184, where the allele frequency in the general
population 8% [9]; this result would have been detected
by fSNPd with a corrected p value of <10−8. Secondly,
deafness caused by aminoglycoside antibiotics found to
be due to the mitochondrial genome SNP rs267606617
(m.1555A > G), would not have been detected by the
fSNPd method, as the mitochondrial genome is not
included in an “exome”, nor was the cohort size of six
individuals sufficient [10]. Thirdly, human immunodefi-
ciency virus infection progression and rs1799987 in the
promotor of the CCR5 gene where the G allele is protect-
ive and has a prevalence of 45% in the general population
and 64% in those with longer survival; this would have
been detected by fSNPd with a corrected p value of <10−6.
Discussion
A number of clear examples are known of disorders
which have both an essential environmental and an
essential genetic component, and for some of these the
etiology is binary; a single environmental trigger and a
single genotype are both required. However, it is unclear
how many diseases/disorders/phenotypes could have this
joint and equal environmental – genetic architecture.
Doubtless this architecture will be a simplification. As a
consequence we have concentrated on the situation of a
single environmental trigger (hence allowing easy cohort
ascertainment) and potentially a number of different,
but each highly penetrant, genetic changes (which could
be in the same or different genes). Adverse drug
reactions are an example of this situation, particularly
idiosyncratic Type B reactions [15]. Some of the geno-
types underlying these reactions have been discovered,
but many have not, e.g. glucose-6-phosphate dehydro-
genase deficiency (multiple mutations in one gene, some
common enough to be known SNPs) who are at signifi-
cant risk of developing acute hemolytic anemia after
sulphonamide administration, and cholinesterase
deficiency which is asymptomatic unless the individual is
given the anesthetic agent suxamethonium which causes
severe prolonged muscle relaxation. There is a need for
greater consideration of this situation; the co-occurrence
in an individual of the environmental trigger and the
genetic change/genotype leads to a significant (>.5)
chance of a resulting human phenotype.
fSNPd has the potential to detect diseases and pheno-
types that require both an environmental trigger event(s),
and the inheritance of a specific susceptible genetic back-
ground. The genetic causes of the phenotypes which
fSNPd is designed to detect are assumed to be complex:
environmental triggers that may be multiple and involve
(at least) age, sex and disease state; phenotype penetrance
may be incomplete (as for many dominant Mendelian
conditions); and multiple independently-penetrant SNP
alleles could each cause a clinically indistinguishable
phenotype. The SNP alleles that can be discovered by
fSNPd would be expected to range from relatively
common (<50%), to very rare (<0.1%).
Our comparison of fSNPd to Mendelian gene discovery
and Association Studies (Table 1) shows that fSNPd can
use far smaller disease/phenotype cohorts compared to
Association studies (10s to 100 s versus 100 s to 10,000 s),
see Additional file 1: Table S2. As a consequence the lesser
cost of association studies per cohort individual is offset
against the greater current cost of an exome. Such smaller
fSNPd cohorts are easier to collect, and to make ethnically
or geographically restricted. As with Association studies,
(See figure on previous page.)
Fig. 1 Diagram of the methodological steps of the input, internal processes and output of the “functional single nucleotide polymorphism discovery”
(fSNPd) program. Legend: The first step is the ascertainment of a cohort of individuals with the phenotype to be studies; blue box. The second step is to
perform exomes (with the same capture and sequencing methods) on a number of the cohort individuals; blue box. The top-most black box shows the
input to fSNPd; number of individuals, number of males and females, and each individuals vcf (and if required, bam+bam.bai) files). Entering the number of
males and females allows fSNP to internally check that it has assigned sex correctly to each sample, so that SNPs on the X chromosome have correct allele
frequencies calculated. A second lower-most black box shows the output of fSNPd, the list of SNPs where the allele frequency is statistically altered compared
to the 1000 Genomes or Exome variant Server European library data. Between the black boxes are shown the processes performed within fSNPd
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the smaller the cohort in fSNPd the greater the chance of
false positive and false negatives for commoner alleles,
and false negatives for rarer alleles [16].
Conclusions
We suggest that the fSNPd approach should be consid-
ered when seeking the highly penetrant genetic compo-
nents for apparently sporadic phenotypes which can be
triggered by environmental events. As the common
causative SNP alleles will be discovered in one experi-
ment, and each SNPs is within a single gene, and the
SNP alleles cause protein changes, then fSNPd has the
potential to facilitate the rapid discovery of underlying
pathophysiology.
Methods
Our aim was to find gene changes with fully penetrant
effects that would cause pain phenotypes. We designed
our approach based on three tenets. Firstly, the SNP
alleles that would individually cause fully penetrant (and
detectable) effects were most likely to be exonic and
protein changing (mis-sense, non-sense, indels, or
splicing). Secondly, an exome would detect the majority
of these SNPs. Thirdly, smaller cohorts are easier to
collect, phenotype and curate.
We wrote the fSNPd program to analyse multiple exomes
simultaneously with the purpose of identifying common
SNP alleles that exist in a population of interest at a signifi-
cantly different frequency than that of the general popula-
tion. To do this, the program first establishes a catalogue of
common SNPs based on an existing cohort; we used the
1000 Genome Project or the Exome Variant Server (EVS) as
both were available at the time to download. Confounding
variables can be limited by choosing a subset of such a
cohort based on ethnicity/location to match the demograph-
ics of the population of interest.
In our experiments, we tested the European subset of the
1000 Genome Project (the UK subset being unfortunately
too small for this purpose – about 100 individuals) and the
EVS, and considered SNPs that differed from at least one of
these at a significant level to be relevant. The 1000 Genome
Project had the advantage of being a better ethnic match
for our cohort (predominantly white Caucasian), while the
EVS had data from a greater number of individuals
(approximately 20,000 individuals). In the final program
fSNPd produces results for both.
The program calculates rare allele frequencies of SNPs
in the population of interest. Individuals’ data is handled
in vcf format (post variant-calling) versus raw sequen-
cing reads, so that each locus is assigned two possible
alleles. Population allele frequencies are determined by
tallying the counts of each allele at each SNP locus
across all of the individuals in the population of interest
and dividing by the total number of presumed alleles at
each locus (two per individual for loci on autosomal
chromosomes and one (male) or two (female) per
individual for those on sex chromosomes).
Finally, allele frequencies per each SNP in the starting
catalogue are compared between the population of interest
and the general population using a two-tailed chi-squared
test without Yates’ correction. SNPs with significantly
higher or lower allele frequencies in the population of inter-
est are identified. Significance is characterized by frequen-
cies that differ by a p-value of 2% or more, with Bonferroni
and false discovery rate (FDR) corrections applied, accord-
ing to the total number of SNPs compared (the number in
the initial catalogue from the existing cohort) [17].
Additionally, for SNPs that do not exist in particular
individuals in the population of interest, raw sequencing
data can be accessed to confirm coverage of the area. If
no coverage exists, fSNPd can calculate upper and lower
bounds of allele frequencies and subsequent p-values.
Table 1 A comparison of the methodologies, strengths and weaknesses of Mendelian gene discovery, Association studies and fSNPd
Mendelian gene discovery Genome Wide Association studies fSNPd
Minimum number of affected individuals/families 2 to 10 families Typically >2000 30–200 individuals
Scope Usually exome Genome Exome
Approach Usually candidate Non-candidate Non-candidate
Proof If linkage p < 0.05 +/−
additional proofs
Conventional threshold
is p < 5 × 10−8
p < 0.01 after correction
for SNPs assessed
Effect on phenotype Fully penetrant for
recessive and X-linked;
dominant penetrance
0.33 to 1.0
Usually very small, e.g. odds
ratio < 1.33 for a risk SNP.
Non-penetrant before
environmental triggers;
presumed 0.5–1.0 penetrance
after trigger.
Approximate cost to perform £10,000–£100,000 £300,000–£8,000,000 £15,000–£50,000
Number of phenotype-associated genes identified 1 >1 >1
Are changes discovered easily
functionally assessed
Yes Usually No Yes
Ability to cope with non-genetic cases Poor Moderate Good
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The data input for the final fSNPd program are each indi-
vidual’s vcf file, and the number of males and females. As an
option the fSNPd program can check the actual read depth
and quality of each SNP called, if this option is selected, each
cohort individuals’ bam and bam.bai files are required. See
Additional file 1: Supplementary data for fSNPd set up, and
URL’s for downloading programs.
We wanted to determine how many SNPs were accur-
ately sequenced in an exome, and so analysed 40 exomes
by fSNPd to determine base by base and exon by exon
coverage. This analysis sought to determine whether
particular genes or exons of genes would be predictably
included in, or missed from, our results.
We assess the performance of fSNPd for allele
frequency determination by analysis of two patient
cohorts (one of 116 individuals, the other of 34). From
the results we selected a sample of SNPs from each
where allele frequencies were found to be statistically
altered and checked the results “by hand” by use of the
Integrated Genome Viewer and by Sanger sequencing of
all of the cohort individuals.
After generating results for all SNPs encompassed by an
exome we chose to examine only those SNPs that would
unequivocally alter proteins (nonsense mutations, start
and stop codon mutations, canonical splice site mutations,
and missense mutations predicted to be potentially patho-
genic). This was for two reasons; such mutations are easier
to assess by bio-informatics analysis, and are more easily
amenable to functional testing to determine their patho-
genicity. Others, however, may seek to examine all of the
SNPs identified by the pipeline.
We simulated the performance of fSNPd under a variety
of conditions, see Additional file 1: Table S2.
fSNPd is freely downloadable, instructions are in the
Supplement [18].
Additional file
Additional file 1: Use of fSNPd and the Supplementary Figure. This
firstly documents the instructions for the installation of fSNPd, and its
use. Secondly, it contains the Supplemental Figure entitled: Average read
depth per base of genes in a test cohort of 40 individuals’ exomes - data
derived from Supplemental Table S1. This shows a graph of calculate
the average read coverage by all genes, and the legend details the
methodology used. References used are given after the legend. Read
number statistics of average depth of sequence reads for each exon of
each gene included in the exomes of forty individuals. This is a large
spreadsheet giving the detailed analysis of read depth achieved. Results
and statistics are given for each gene and exon of each gene. Thus, the
coverage of an exome of any desired exon can be determined.
Simulations of the performance of fSNPd compared to an Association
study approach in a variety of scenarios. Simulations were performed
assuming that a rare SNP allele was fully penetrant when present (unless
otherwise stated). For each Simulation SNP-1 is a common SNP (such as
are used in Association studies) with allele A frequency = allele B
frequency = 0.5 and SNP-2 (analysed in fSNPd) has the rare allele A
frequency = .01 and the common allele B frequency = .99. The SNP-2
allele A is disease associated and always on a SNP-1 allele A background.
Simulation are of: the number of SNPs causing a phenotype; different
SNP-2 rare allele frequencies; if half of cases are non-genetic or rare SNPs
allele penetrance 50%; and of using a cohort size of 3000, rather than
100 as used for all other simulations. (ZIP 8041 kb)
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